89. Lymphangioleiomyomatosis
38 clinical trials,   42 drugs   (DrugBank: 19 drugs),   26 drug target genes,   134 drug target pathways
Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01799538 (ClinicalTrials.gov) | June 10, 2013 | 23/2/2013 | Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis | 13-H-0051 Bronchodilator Effects of Nebulized Versus Inhaled Albuterol in Subjects With Lymphangioleiomyomatosis | Lymphangioleiomyomatosis | Drug: albuterol inhaler;Drug: albuterol nebulizer;Procedure: PFT | National Heart, Lung, and Blood Institute (NHLBI) | NULL | Recruiting | 18 Years | 80 Years | Female | 100 | Phase 2 | United States |